Inclusion Criteria:

• Patients must have the ability to provide Informed Consent.
• Female patients of childbearing potential must have a negative pregnancy test at Screening, must use adequate contraception.
• Patients must have a medical condition compatible with EPI.
• Patients with Chronic Pancreatitis due to alcohol abuse may be included provided they show no clinical symptoms of recent alcohol consumption and no alcohol withdrawal symptoms.
• Patients with Chronic Pancreatitis.
• Patients must have evidence of EPI as demonstrated by a fecal Elastase determination.
• Patients must have evidence of EPI as manifested by a Coefficient of Fat Absorption (CFA%).

Exclusion Criteria:

• Patients with a known hypersensitivity and/or contraindication to any of the study medications, to their excipients or to their components.
• Patients with acute pancreatitis or with an acute exacerbation of Chronic Pancreatitis.
• Patients with any active or recurrent malignant pancreatic tumor.
• Patients with a history of significant bowel resection.
• Patients with a dysmotility disorder.
• Patients with insufficient body mass (i.e. Body Mass Index < 18).
• Patients known to have a significant medical and/or mental disease that would compromise the patient's welfare or confound the study results.
• Patients with a history of fibrosing colonopathy, cirrhosis of the liver, or portal hypertension.
• Patients with a known allergy to the FD&C Blue No. 2 dye marker.
• Patients who have a condition known to increase fecal fat loss.
• Female patients who are pregnant or breastfeeding.
• Patients who have received an Investigational drug within 30 days prior to entering the screening phase of the study.
• Causes for EPI other than Chronic Pancreatitis and partial/total pancreas resection.
• Patients with a history or clinical evidence of any relevant cardio- or cerebrovascular, renal, endocrine, neurologic, infectious, other gastrointestinal, hematological, oncological or psychiatric disease or emotional problems.